Simon R Lord (S Lord, Simon Lord, S R Lord)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 29

Top Topics

Squamous Cell Carcinoma

Top Venues

British journal of cancer

Nature communications

NPJ breast cancer

Exploration of targeted anti-tumor therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Sohail Rooman Javed, Aglaia Skolariki, Mohammed Zeeshan Zameer, Simon R Lord
Implications of obesity and insulin resistance for the treatment of oestrogen receptor-positive breast cancer. British journal of cancer (2024)
S R Javed, Simon R Lord, S El Badri, R Harman, J Holmes, F Kamzi, Timothy S Maughan, David McIntosh, S Mukherjee, A Ooms, G Radhakrishna, P Shaw, Maria A Hawkins
CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method. British journal of cancer 130 (3) (2023)
Valentine Moya Macaulay, Simon R Lord, Syed Anwer Hussain, José Pablo Maroto, Robert Hugh Jones, Miguel Ángel Climent, Natalie Cook, Chia-Chi Lin, Shian-Shiang Wang, Diletta Bianchini, Mark Bailey, Laura Schlieker, Thomas Bogenrieder, Johann de Bono
A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer. British journal of cancer (2023)
Simon R Lord, Adrian L Harris
Is it still worth pursuing the repurposing of metformin as a cancer therapeutic? British journal of cancer 128 (6) (2023)
Simon R Lord, Adrian L Harris
Is it still worth pursuing the repurposing of metformin as a cancer therapeutic? British journal of cancer 128 (6) (2023)
Raoul Charles Coombes, Sacha Howell, Simon R Lord, Laura Kenny, Janine Mansi, Zahi I Mitri, Carlo Palmieri, Linnea I Chap, Paul Richards, William J Gradishar, Sagar Sardesai, Jason Melear, Joyce O'Shaughnessy, Patrick J Ward, Pavani Chalasani, Tobias Arkenau, Richard D Baird, Rinath M Jeselsohn, Simak Ali, Glen Clack, Ashwani Bahl, Stuart McIntosh, Matthew G Krebs
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib. Nature communications 14 (1) (2023)
S R Javed, Simon R Lord, S El Badri, R Harman, J Holmes, F Kamzi, Timothy S Maughan, David McIntosh, S Mukherjee, A Ooms, G Radhakrishna, P Shaw, Maria A Hawkins
CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method. British journal of cancer 130 (3) (2023)
Raoul Charles Coombes, Sacha Howell, Simon R Lord, Laura Kenny, Janine Mansi, Zahi I Mitri, Carlo Palmieri, Linnea I Chap, Paul Richards, William J Gradishar, Sagar Sardesai, Jason Melear, Joyce O'Shaughnessy, Patrick J Ward, Pavani Chalasani, Tobias Arkenau, Richard D Baird, Rinath M Jeselsohn, Simak Ali, Glen Clack, Ashwani Bahl, Stuart McIntosh, Matthew G Krebs
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib. Nature communications 14 (1) (2023)
S R Javed, Simon R Lord, S El Badri, R Harman, J Holmes, F Kamzi, Timothy S Maughan, David McIntosh, S Mukherjee, A Ooms, G Radhakrishna, P Shaw, Maria A Hawkins
CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method. British journal of cancer 130 (3) (2023)
S R Javed, Simon R Lord, S El Badri, R Harman, J Holmes, F Kamzi, Timothy S Maughan, David McIntosh, S Mukherjee, A Ooms, G Radhakrishna, P Shaw, Maria A Hawkins
CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method. British journal of cancer (2023)
Peter A Henriksen, Peter S Hall, Iain R J Macpherson, Shruti S Joshi, Trisha Singh, Morag Maclean, Stephanie Lewis, Aryelly Rodriguez, Alexander J Fletcher, Russell J Everett, Harriet Stavert, Angus Broom, Lois Eddie, Lorraine Primrose, Heather McVicars, Pamela McKay, Annabel Borley, Clare Rowntree, Simon R Lord, Graham P Collins, John Radford, Amy Guppy, Michelle Claire Williams, Alan Japp, John R Payne, David E Newby, Nicholas L Mills, Olga Oikonomidou, Ninian N Lang
Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial. Circulation (2023)
S R Javed, Simon R Lord, S El Badri, R Harman, J Holmes, F Kamzi, Timothy S Maughan, David McIntosh, S Mukherjee, A Ooms, G Radhakrishna, P Shaw, Maria A Hawkins
CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method. British journal of cancer 130 (3) (2023)
Simon R Lord, Adrian L Harris
Is it still worth pursuing the repurposing of metformin as a cancer therapeutic? British journal of cancer 128 (6) (2023)
S R Javed, Simon R Lord, S El Badri, R Harman, J Holmes, F Kamzi, Timothy S Maughan, David McIntosh, S Mukherjee, A Ooms, G Radhakrishna, P Shaw, Maria A Hawkins
CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method. British journal of cancer 130 (3) (2023)
S R Javed, Simon R Lord, S El Badri, R Harman, J Holmes, F Kamzi, Timothy S Maughan, David McIntosh, S Mukherjee, A Ooms, G Radhakrishna, P Shaw, Maria A Hawkins
CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method. British journal of cancer 130 (3) (2023)
Simon R Lord, Adrian L Harris
Is it still worth pursuing the repurposing of metformin as a cancer therapeutic? British journal of cancer 128 (6) (2023)
Simon R Lord, Adrian L Harris
Is it still worth pursuing the repurposing of metformin as a cancer therapeutic? British journal of cancer 128 (6) (2023)
Simon R Lord, Adrian L Harris
Is it still worth pursuing the repurposing of metformin as a cancer therapeutic? British journal of cancer (2023)
S R Javed, Simon R Lord, S El Badri, R Harman, J Holmes, F Kamzi, Timothy S Maughan, David McIntosh, S Mukherjee, A Ooms, G Radhakrishna, P Shaw, Maria A Hawkins
CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method. British journal of cancer 130 (3) (2023)
Simon R Lord, Adrian L Harris
Is it still worth pursuing the repurposing of metformin as a cancer therapeutic? British journal of cancer (2023)
Peter A Henriksen, Peter S Hall, Olga Oikonomidou, Iain R J Macpherson, Morag Maclean, Stephanie Lewis, Heather McVicars, Angus Broom, Fiona Scott, Pamela McKay, Annabel Borley, Clare Rowntree, Simon R Lord, Graham Collins, John Radford, Amy Guppy, John R Payne, David E Newby, Nicholas L Mills, Ninian N Lang
Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity. Circulation. Heart failure 15 (7) (2022)
Aglaia Skolariki, Jamie D'Costa, Martin Little, Simon R Lord
Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic. Exploration of targeted anti-tumor therapy 3 (2) (2022)
Melinda L Telli, Sara M Tolaney, Geoffrey I Shapiro, Mark Middleton, Simon R Lord, Hendrik Tobias Arkenau, Andrew N J Tutt, Vandana Abramson, Emma Dean, Tufia C Haddad, Robert Wesolowski, Jordi Ferrer-Playan, Thomas Goddemeier, Thomas Grombacher, Jennifer Dong, Patricia Fleuranceau-Morel, Ivan Diaz-Padilla, Ruth Plummer
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer. NPJ breast cancer 8 (1) (2022)
Vinton W T Cheng, Nicholas de Pennington, Rasheed Zakaria, James R Larkin, Sébastien Serres, Manjima Sarkar, Matthew A Kirkman, Claire Bristow, Paula Croal, Puneet Plaha, Leticia Campo, Michael A Chappell, Simon R Lord, Michael D Jenkinson, Mark Ross Middleton, Nicola R Sibson
VCAM-1-targeted MRI Improves Detection of the Tumor-brain Interface. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (11) (2022)
N P Scott, E J Teoh, H Flight, B E Jones, J Niederer, L Mustata, G M MacLean, P G Roy, D D Remoundos, Cameron E Snell, C Liu, F V Gleeson, Adrian L Harris, Simon R Lord, Daniel R McGowan
Characterising 18F-fluciclovine uptake in breast cancer through the use of dynamic PET/CT imaging. British journal of cancer (2021)
Ashley Kieran Clift, David Dodwell, Simon R Lord, Stavros Petrou, Sir Michael Brady, Gary Stephen Collins, Julia Hippisley-Cox
The current status of risk-stratified breast screening. British journal of cancer (2021)
Geoffrey I Shapiro, Robert Wesolowski, Craig Devoe, Simon R Lord, John Pollard, Bart S Hendriks, Martin Falk, Ivan Diaz-Padilla, Ruth Plummer, Timothy Anthony Yap
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours. British journal of cancer 125 (4) (2021)
Simon R Lord, Jennifer M Collins, Wei-Chen Cheng, Syed Haider, Simon Wigfield, Edoardo Gaude, Barbara A Fielding, Katherine E Pinnick, Ulrike Harjes, Ashvina Segaran, Pooja Jha, Gerald Hoefler, Michael N Pollak, Alastair M Thompson, Pankaj G Roy, Ruth English, Rosie F Adams, Christian Frezza, Francesca M Buffa, Fredrik Karpe, Adrian L Harris
Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin. British journal of cancer 122 (2) (2019)
Francesca Aroldi, Simon R Lord
Window of opportunity clinical trial designs to study cancer metabolism. British journal of cancer 122 (1) (2019)